Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Paladin spins off Knight Therapeutics with ownership of orphan drug Impavido

Executive Summary

Drug in-licenser Paladin Labs Inc. spun off Knight Therapeutics Inc., a new public company that will own rights to Paladin’s Impavido (miltefosine), an orphan product for leishmaniasis. The spin-off is concurrent with Endo Health Solutions Inc.’s $1.5bn purchase of Paladin.
Deal Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register